323 related articles for article (PubMed ID: 21034692)
1. Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial.
Saricicek A; Maloney K; Muralidharan A; Ruf B; Blumberg HP; Sanacora G; Lorberg B; Pittman B; Bhagwagar Z
J Clin Psychiatry; 2011 Jun; 72(6):744-50. PubMed ID: 21034692
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).
Young AH; McElroy SL; Bauer M; Philips N; Chang W; Olausson B; Paulsson B; Brecher M;
J Clin Psychiatry; 2010 Feb; 71(2):150-62. PubMed ID: 20122369
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).
McElroy SL; Weisler RH; Chang W; Olausson B; Paulsson B; Brecher M; Agambaram V; Merideth C; Nordenhem A; Young AH;
J Clin Psychiatry; 2010 Feb; 71(2):163-74. PubMed ID: 20122366
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
[TBL] [Abstract][Full Text] [Related]
5. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
Sachs GS; Ice KS; Chappell PB; Schwartz JH; Gurtovaya O; Vanderburg DG; Kasuba B
J Clin Psychiatry; 2011 Oct; 72(10):1413-22. PubMed ID: 21672493
[TBL] [Abstract][Full Text] [Related]
7. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?
Lombardo I; Sachs G; Kolluri S; Kremer C; Yang R
J Clin Psychopharmacol; 2012 Aug; 32(4):470-8. PubMed ID: 22722504
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.
Calabrese JR; Keck PE; Macfadden W; Minkwitz M; Ketter TA; Weisler RH; Cutler AJ; McCoy R; Wilson E; Mullen J
Am J Psychiatry; 2005 Jul; 162(7):1351-60. PubMed ID: 15994719
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
Mischoulon D; Witte J; Levy M; Papakostas GI; Pet LR; Hsieh WH; Pencina MJ; Ward S; Pollack MH; Fava M
J Clin Psychiatry; 2012 Mar; 73(3):353-7. PubMed ID: 21939613
[TBL] [Abstract][Full Text] [Related]
10. Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial.
Juruena MF; Ottoni GL; Machado-Vieira R; Carneiro RM; Weingarthner N; Marquardt AR; Fleig SS; Broilo L; Busnello EA
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Feb; 33(1):94-9. PubMed ID: 19007842
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).
Thase ME; Macfadden W; Weisler RH; Chang W; Paulsson B; Khan A; Calabrese JR;
J Clin Psychopharmacol; 2006 Dec; 26(6):600-9. PubMed ID: 17110817
[TBL] [Abstract][Full Text] [Related]
12. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study.
Vieta E; Calabrese JR; Goikolea JM; Raines S; Macfadden W;
Bipolar Disord; 2007 Jun; 9(4):413-25. PubMed ID: 17547587
[TBL] [Abstract][Full Text] [Related]
13. Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double-blind, placebo-controlled study.
Stamm TJ; Lewitzka U; Sauer C; Pilhatsch M; Smolka MN; Koeberle U; Adli M; Ricken R; Scherk H; Frye MA; Juckel G; Assion HJ; Gitlin M; Whybrow PC; Bauer M
J Clin Psychiatry; 2014 Feb; 75(2):162-8. PubMed ID: 24345793
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
Septien-Velez L; Pitrosky B; Padmanabhan SK; Germain JM; Tourian KA
Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
[TBL] [Abstract][Full Text] [Related]
15. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder.
DelBello MP; Chang K; Welge JA; Adler CM; Rana M; Howe M; Bryan H; Vogel D; Sampang S; Delgado SV; Sorter M; Strakowski SM
Bipolar Disord; 2009 Aug; 11(5):483-93. PubMed ID: 19624387
[TBL] [Abstract][Full Text] [Related]
17. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen.
Yildiz A; Guleryuz S; Ankerst DP; Ongür D; Renshaw PF
Arch Gen Psychiatry; 2008 Mar; 65(3):255-63. PubMed ID: 18316672
[TBL] [Abstract][Full Text] [Related]
19. A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type.
Roy Chengappa K; Kupfer DJ; Parepally H; John V; Basu R; Buttenfield J; Schlicht P; Houck P; Brar JS; Gershon S
Bipolar Disord; 2007 Sep; 9(6):609-17. PubMed ID: 17845276
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
